228 related articles for article (PubMed ID: 26582061)
1. Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.
Kastrinos F; Ojha RP; Leenen C; Alvero C; Mercado RC; Balmaña J; Valenzuela I; Balaguer F; Green R; Lindor NM; Thibodeau SN; Newcomb P; Win AK; Jenkins M; Buchanan DD; Bertario L; Sala P; Hampel H; Syngal S; Steyerberg EW;
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582061
[TBL] [Abstract][Full Text] [Related]
2. Prediction of germline mutations and cancer risk in the Lynch syndrome.
Chen S; Wang W; Lee S; Nafa K; Lee J; Romans K; Watson P; Gruber SB; Euhus D; Kinzler KW; Jass J; Gallinger S; Lindor NM; Casey G; Ellis N; Giardiello FM; Offit K; Parmigiani G;
JAMA; 2006 Sep; 296(12):1479-87. PubMed ID: 17003396
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Lynch syndrome in consecutive patients with colorectal cancer.
Green RC; Parfrey PS; Woods MO; Younghusband HB
J Natl Cancer Inst; 2009 Mar; 101(5):331-40. PubMed ID: 19244167
[TBL] [Abstract][Full Text] [Related]
4. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients.
Balmaña J; Balaguer F; Castellví-Bel S; Steyerberg EW; Andreu M; Llor X; Jover R; Castells A; Syngal S;
J Med Genet; 2008 Sep; 45(9):557-63. PubMed ID: 18603628
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.
Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H
Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of the PREMM
Kastrinos F; Uno H; Ukaegbu C; Alvero C; McFarland A; Yurgelun MB; Kulke MH; Schrag D; Meyerhardt JA; Fuchs CS; Mayer RJ; Ng K; Steyerberg EW; Syngal S
J Clin Oncol; 2017 Jul; 35(19):2165-2172. PubMed ID: 28489507
[TBL] [Abstract][Full Text] [Related]
7. A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers.
Pouchet CJ; Wong N; Chong G; Sheehan MJ; Schneider G; Rosen-Sheidley B; Foulkes W; Tischkowitz M
Ann Oncol; 2009 Apr; 20(4):681-8. PubMed ID: 19164453
[TBL] [Abstract][Full Text] [Related]
8. Criteria and prediction models for mismatch repair gene mutations: a review.
Win AK; Macinnis RJ; Dowty JG; Jenkins MA
J Med Genet; 2013 Dec; 50(12):785-93. PubMed ID: 23956446
[TBL] [Abstract][Full Text] [Related]
9. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
[TBL] [Abstract][Full Text] [Related]
10. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
[TBL] [Abstract][Full Text] [Related]
11. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
[TBL] [Abstract][Full Text] [Related]
12. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
[TBL] [Abstract][Full Text] [Related]
13. Prediction of MLH1 and MSH2 mutations in Lynch syndrome.
Balmaña J; Stockwell DH; Steyerberg EW; Stoffel EM; Deffenbaugh AM; Reid JE; Ward B; Scholl T; Hendrickson B; Tazelaar J; Burbidge LA; Syngal S
JAMA; 2006 Sep; 296(12):1469-78. PubMed ID: 17003395
[TBL] [Abstract][Full Text] [Related]
14. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.
Ait Ouakrim D; Dashti SG; Chau R; Buchanan DD; Clendenning M; Rosty C; Winship IM; Young JP; Giles GG; Leggett B; Macrae FA; Ahnen DJ; Casey G; Gallinger S; Haile RW; Le Marchand L; Thibodeau SN; Lindor NM; Newcomb PA; Potter JD; Baron JA; Hopper JL; Jenkins MA; Win AK
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26109217
[TBL] [Abstract][Full Text] [Related]
15. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
[TBL] [Abstract][Full Text] [Related]
16. Performance of Lynch syndrome predictive models in quantifying the likelihood of germline mutations in patients with abnormal MLH1 immunoexpression.
Cabreira V; Pinto C; Pinheiro M; Lopes P; Peixoto A; Santos C; Veiga I; Rocha P; Pinto P; Henrique R; Teixeira MR
Fam Cancer; 2017 Jan; 16(1):73-81. PubMed ID: 27581132
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
Piñol V; Castells A; Andreu M; Castellví-Bel S; Alenda C; Llor X; Xicola RM; Rodríguez-Moranta F; Payá A; Jover R; Bessa X;
JAMA; 2005 Apr; 293(16):1986-94. PubMed ID: 15855432
[TBL] [Abstract][Full Text] [Related]
18. Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome.
Barrow E; Jagger E; Brierley J; Wallace A; Evans G; Hill J; McMahon R
Histopathology; 2010 Feb; 56(3):331-44. PubMed ID: 20459533
[TBL] [Abstract][Full Text] [Related]
19. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States.
Kastrinos F; Stoffel EM; Balmaña J; Steyerberg EW; Mercado R; Syngal S
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2044-51. PubMed ID: 18708397
[TBL] [Abstract][Full Text] [Related]
20. A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting.
Ramsoekh D; Wagner A; van Leerdam ME; Dinjens WN; Steyerberg EW; Halley DJ; Kuipers EJ; Dooijes D
Gut; 2008 Nov; 57(11):1539-44. PubMed ID: 18625694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
